DELHI, India, July 06, 2021 (GLOBE NEWSWIRE) -- Global Peptide Drug Conjugate Market & Clinical Trials Insight 2026 Report Highlights:
- First FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide)
- Pepaxto Clinical & Commercial Insight: Dosage, Patent, Price, Sales Forecast
- Peptide Drug Conjugate Sales Opportunity: US, Europe, Japan & South Korea
- Global Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs
- Clinical Trials Insight by Company, Country, Indication
- Patent Insight of Peptide Drug Conjugates
- Profile & Clinical Pipeline Insight of Companies Developing Peptide Drug Conjugates
Download Report:
“Global Peptide Drug Conjugate Market & Clinical Trials Insight 2026” provides comprehensive insight on clinical and non clinical factors that are driving the peptide drug conjugate market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the commercial opportunity and clinical insight on only approved peptide drug conjugate Pepaxto. Report also includes insight on more than 20 approved peptide drug conjugates in clinical pipeline.
This Report is bases upon the combinational approach of secondary and primary research which is further backed up by access to open and paid up databases. The company financial reports, quarterly disclosures, company news, market updates, industry journal’s, drug clinical updates and drug sales releases are used as the fundamental premise for all the market estimates, drug sales data, patent insight, clinical approved dosage information and other data indicators encapsulated in "Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026" report. Any clinical and commercial insight included in our repot is thoroughly compiled, analyzed and verified from credible paid and open ended sources.
During the past few decades, peptides have gained wide range of applications in medicine and biotechnology, and therapeutic peptide research is also currently experiencing renaissance for commercial reasons. Given their small size, peptides have the ability to infiltrate deeper into the target tissue than proteins. Additionally, therapeutic peptides are less immunogenic and more cost-efficient to manufacture. As of now, about 60 peptide based drugs have been approved in US and other markets which have shown robust clinical response in management of several diseases including cancer.
The development of peptide drug conjugates have shown to have significant benefits over other conventional therapies. As peptides are readily cleaved by proteolytic enzymes, thus they are rapidly cleared from kidney. Furthermore, their low molecular weight leads to enhanced penetration into solid tumors resulting in robust anti-tumor response. Apart from this, the therapy is also used in patients who are unresponsive to other currently available therapies, thus increasing their uptake in market.
Currently, only one peptide drug conjugate has been approved for the management of cancer. Pepaxto (melphalan flufenamide) was recent granted approval in February, 2021 for the management of multiple myeloma. The robust clinical response of the drug in clinical studies and the rapid approval of first in class drug have initiated a lot of research and development activities in this field. As of now, many peptide drug conjugates are in the development phase of preclinical and clinical studies which are expected to enter the market in next few years.
Contact:
Neeraj Chawla
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com